This paper examines the controversy that surrounded plans by Hoechst to bui
ld a facility in Germany to manufacture human insulin using gene technology
. Social and political factors that framed lay and expert understandings of
gene technology and attitudes to risk in the dispute will be examined. It
is argued that the formal regulatory and dispute resolution arenas privileg
ed a technical-risk-as-rational-choice model of decision making as the "nat
ural'' ordering of risk and the understanding of gene technology in the dis
pute. This had the effect of overburdening technical risk as the cause of t
he controversy, leading to an asymmetrical treatment of scientific and non-
scientific knowledge and drawing the facility's opponents into the very dis
course on gene technology they wanted to challenge. In the end, the policy
procedures were unsuccessful in resolving the controversy because they fail
ed to address many of the issues that the public and the opponents regarded
as important.